Lifeboat Foundation

Scientists at the Leibniz Institute of Plant Biochemistry (IPB) have succeeded for the first time in stably and precisely inserting large gene segments into the DNA of higher plants very efficiently. To do this, they optimized the gene-editing method CRISPR/Cas, commonly known as “genetic scissors.”

The improved CRISPR method offers great opportunities for the targeted modification of genes in higher plants, both for breeding and research. The study, led by Prof. Alain Tissier and Dr. Tom Schreiber, has been published in Molecular Plant.

CRISPR/Cas is a method with enormous potential for the targeted modification of individual genes. However, this does not apply to all kinds of genetic modifications that breeders and scientists have on their wish lists. While the genetic scissors are ideal for knocking out genes, i.e., switching off or removing existing genes, they do not work well for precisely inserting genes or replacing gene segments. To date, genetic scissors have been too inefficient and therefore of little use for the targeted insertion of genes into the DNA of higher plants.

Paralog synthetic lethals have been assessed with multiple CRISPR-based methods, but systematic comparison among these platforms is unavailable. Here, the authors systematically compare combinatorial perturbation platforms and establish the in4mer CRISPR/Cas12a multiplex knockout platform.

Vaccination has beaten back infections for more than a century. Now, it may be the next big step in battling cancer.

A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a condition that causes rapid abnormal heart rhythms. The study, published March 25 in the Journal of the American College of Cardiology, provides real-world evidence that a wide range of patients can safely and effectively use the experimental drug, called etripamil, to treat recurrent paroxysmal supraventricular tachycardia (PSVT) episodes at home, potentially sparing them the need for repeated hospital trips for more invasive treatments.

The study is the latest in a series of studies by lead author Dr. James Ip, professor of clinical medicine at Weill Cornell Medicine and a cardiologist at New York-Presbyterian/Weill Cornell Medical Center, and colleagues to demonstrate the potential of nasal spray calcium-channel blocker etripamil as an at-home treatment PSVT.

Dr. Ip received compensation as a steering committee member for Milestone Pharmaceuticals, the maker of etripamil and sponsor of the trial.

A new paper that combines antigenic analysis of dengue virus with two decades of hospital data in Thailand teases apart how different combinations of serotypes shape the risk of severe secondary infections in children.

In a new study, a Yale Pathology team has identified a possible therapeutic target for treating obesity-induced liver cancer.

Researchers say inhibiting a molecule called fatty acid binding protein 5 (FABP5) could block tumor progression in many cases:

Inhibiting a certain protein in mice reduced obesity-induced liver tumor development, Yale researchers found. It could reveal a future treatment route.

Continue reading “Study identifies driver of liver cancer that could be target for treatment” »

An antibody screen of two distinct multiple sclerosis cohorts reveals an autoantibody signature that is detectable years before symptom onset and linked to a common microbial motif, according to a paper in Nature Medicine. Read the paper:

Abstract. In recent years, brain research has indisputably entered a new epoch, driven by substantial methodological advances and digitally enabled data integration and modelling at multiple scales—from molecules to the whole brain. Major advances are emerging at the intersection of neuroscience with technology and computing. This new science of the brain combines high-quality research, data integration across multiple scales, a new culture of multidisciplinary large-scale collaboration, and translation into applications. As pioneered in Europe’s Human Brain Project (HBP), a systematic approach will be essential for meeting the coming decade’s pressing medical and technological challenges.

The hypertension drug rilmenidine has been shown to slow down aging in worms, an effect that in humans could hypothetically help us live longer and keep us healthier in our latter years.

Previous research has shown rilmenidine mimics the effects of caloric restriction on a cellular level. Reducing available energy while maintaining nutrition within the body has been shown to extend lifespans in several animal models.

Whether this translates to human biology, or is a potential risk to our health, is a topic of ongoing debate. Finding ways to achieve the same benefits without the costs of extreme calorie cutting could lead to new ways to improve health in old age.